Zhou Shufeng, Kestell Philip, Paxton James W
Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand.
J Pharm Pharmacol. 2002 Jul;54(7):997-1003. doi: 10.1211/002235702760089135.
Total (added) drug concentrations other than unbound concentrations have been used to estimate the in-vitro enzyme kinetic parameters for 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an experimental anti-cancer drug. This study aimed to investigate the non-specific binding of DMXAA to liver microsomes from variousspecies and to microsomesfrom human lymphoblastoid cells expressing drug-metabolising enzymes, and to examine the effect of the binding on the estimation of enzyme kinetic parameters for DMXAA in-vitro. The separation of unbound DMXAA was conducted by ultrafiltration and DMXAA concentrations were determined by validated HPLC. The results indicated that DMXAA was bound to liver microsomes and lymphoblastoid cell microsomes to a small extent (free fraction in microsomes, f(u(mic)) mostly > 0.85). Correction forthe unbound DMXAA concentration resulted in slightly lower apparent Michaelis-Menten constant (Km) values, but with the maximal velocity of reaction (Vmax) unchanged, leading to slightly higher unbound Vmax/Km values. These results indicate that the non-specific binding of DMXAA to microsomes is insignificant and has little impact on the enzyme kinetic estimation in-vitro.
除游离浓度外的总(加和)药物浓度已被用于估算实验性抗癌药物5,6-二甲基呫吨酮-4-乙酸(DMXAA)的体外酶动力学参数。本研究旨在考察DMXAA与不同物种肝脏微粒体以及表达药物代谢酶的人淋巴母细胞微粒体的非特异性结合情况,并研究这种结合对体外估算DMXAA酶动力学参数的影响。通过超滤分离游离的DMXAA,并采用经过验证的高效液相色谱法测定DMXAA浓度。结果表明,DMXAA与肝脏微粒体和淋巴母细胞微粒体有少量结合(微粒体中的游离分数f(u(mic))大多>0.85)。对游离DMXAA浓度进行校正后,表观米氏常数(Km)值略有降低,但反应最大速度(Vmax)不变,导致游离Vmax/Km值略有升高。这些结果表明,DMXAA与微粒体的非特异性结合不显著,对体外酶动力学估算影响不大。